Wedbush Reiterates Neutral on Praxis Precision Medicine, Maintains $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated a Neutral rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintained a $2 price target.
October 03, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush analyst Laura Chico has reiterated a Neutral rating on Praxis Precision Medicine and maintained a $2 price target.
The news directly pertains to Praxis Precision Medicine (PRAX) as the company's stock has been reiterated with a Neutral rating by Wedbush. This suggests that the analyst sees the stock as fairly valued at its current price, which could influence investors' decisions. However, as the rating is neutral, it is not expected to have a significant impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100